Updates on efficacy and safety outcomes of new and emerging disease modifying therapies and stem cell therapy for Multiple Sclerosis: A review

Orelabrutinib: First Approval

(2021) Sohita Dhillon   DRUGS

Diagnosis and Treatment of Multiple Sclerosis

(2021) Marisa P. McGinley et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions

(2021) Marisa P McGinley et al.   LANCET

Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial

(2021) Daniel S Reich et al.   LANCET NEUROLOGY

Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy

(2021) Sokratis A. Apostolidis et al.   NATURE MEDICINE

Disease-modifying therapies and progressive multifocal leukoencephalopathy in multiple sclerosis: A systematic review and meta-analysis

(2021) Shitiz Sriwastava et al.   JOURNAL OF NEUROIMMUNOLOGY

Insight in booster COVID-19 vaccine and disease modifying therapy in multiple sclerosis

(2021) Katherine Beard et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Humoral- and T-Cell–Specific Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients With MS Using Different Disease-Modifying Therapies

(2021) Carla Tortorella et al.   NEUROLOGY

Nanocatalytic activity of clean-surfaced, faceted nanocrystalline gold enhances remyelination in animal models of multiple sclerosis

(2020) Andrew P. Robinson et al.   Scientific Reports

A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis

(2020) Edward Fox et al.   Multiple Sclerosis Journal

Vidofludimus calcium, a next generation DHODH inhibitor for the Treatment of relapsing-remitting multiple sclerosis

(2020) Andreas Muehler et al.   Multiple Sclerosis and Related Disorders

Effects of MS disease-modifying therapies on responses to vaccinations: A review.

(2020) John Robert Ciotti et al.   Multiple Sclerosis and Related Disorders

Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis

(2019) Xavier Montalban et al.   NEW ENGLAND JOURNAL OF MEDICINE

Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases: updated guidelines and recommendations from the EBMT Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of EBMT and ISCT (JACIE)

(2019) Basil Sharrack et al.   BONE MARROW TRANSPLANTATION

Efficacy and Safety of the Newer Multiple Sclerosis Drugs Approved Since 2010

(2018) Simon Faissner et al.   CNS DRUGS

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

(2018) Ludwig Kappos et al.   LANCET

Effects of ATX-MS-1467 immunotherapy over 16 weeks in relapsing multiple sclerosis

(2018) Jeremy Chataway et al.   NEUROLOGY

Clinical Course of Multiple Sclerosis

(2018) Sylvia Klineova et al.   Cold Spring Harbor Perspectives in Medicine

Natural Killer Cells Regulate Th17 Cells After Autologous Hematopoietic Stem Cell Transplantation for Relapsing Remitting Multiple Sclerosis

(2018) Peter J. Darlington et al.   Frontiers in Immunology

Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis

(2018) Robert J. Fox et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and safety of autologous hematopoietic stem-cell transplantation in multiple sclerosis: a systematic review and meta-analysis

(2018) Fangfang Ge et al.   NEUROLOGICAL SCIENCES

Two-year results from a phase 2 extension study of oral amiselimod in relapsing multiple sclerosis

(2017) Ludwig Kappos et al.   Multiple Sclerosis Journal

Intense immunosuppression followed by autologous haematopoietic stem cell transplantation as a therapeutic strategy in aggressive forms of multiple sclerosis

(2017) Gianluigi Mancardi et al.   Multiple Sclerosis Journal

Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis

(2017) Paolo A. Muraro et al.   Nature Reviews Neurology

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

(2017) Xavier Montalban et al.   NEW ENGLAND JOURNAL OF MEDICINE

Two-year results from a phase 2 extension study of oral amiselimod in relapsing multiple sclerosis

(2017) Ludwig Kappos et al.   Multiple Sclerosis Journal

Intense immunosuppression followed by autologous haematopoietic stem cell transplantation as a therapeutic strategy in aggressive forms of multiple sclerosis

(2017) Gianluigi Mancardi et al.   Multiple Sclerosis Journal

Evaluation of No Evidence of Disease Activity in a 7-Year Longitudinal Multiple Sclerosis Cohort

(2015) Dalia L. Rotstein et al.   JAMA Neurology

Epstein–Barr virus-specific adoptive immunotherapy for progressive multiple sclerosis

(2014) Michael P Pender et al.   Multiple Sclerosis Journal

Diminished Th17 (not Th1) responses underlie multiple sclerosis disease abrogation after hematopoietic stem cell transplantation

(2012) Peter J. Darlington et al.   ANNALS OF NEUROLOGY

Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study

(2012) Patrick Vermersch et al.   BMC Neurology

Pharmacological effects of CS-0777, a selective sphingosine 1-phosphate receptor-1 modulator: Results from a 12-week, open-label pilot study in multiple sclerosis patients

(2012) James B. Moberly et al.   JOURNAL OF NEUROIMMUNOLOGY